Cogent Biosciences (NASDAQ:COGT – Get Free Report) was downgraded by investment analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued on Monday, FinViz reports. They presently have a $5.00 price target on the technology company’s stock. Wedbush’s target price indicates a potential upside of 24.69% from the company’s […]
Commodore Capital LP lifted its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 16.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,566,026 shares of the technology company’s stock after acquiring an additional 793,605 shares during the period. […]
Needham & Company LLC restated their buy rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $22.00 price objective on the technology company’s stock. Other research analysts have also issued reports about the stock. Wedbush reissued an outperform rating […]
Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) shares were up 5.1% on Thursday . The company traded as high as $7.87 and last traded at $7.83. Approximately 60,076 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 738,268 shares. The stock had previously closed at $7.45. Wall […]
Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) has earned a consensus rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued a report on the stock in […]